132 related articles for article (PubMed ID: 34144258)
21. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR
Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067
[TBL] [Abstract][Full Text] [Related]
22. A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma.
Porter J; Ding Y; Hale SJM; Perrins RD; Robinson A; Mazanetz MP; Wu Y; Ma Y; Conlon K; Coulter T
Bioorg Med Chem Lett; 2020 Dec; 30(24):127634. PubMed ID: 33148516
[TBL] [Abstract][Full Text] [Related]
23. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
[TBL] [Abstract][Full Text] [Related]
24. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.
Lai KC; Deckert J; Setiady YY; Shah P; Wang L; Chari R; Lambert JM
Pharm Res; 2015 Nov; 32(11):3593-603. PubMed ID: 25630819
[TBL] [Abstract][Full Text] [Related]
26. A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin.
Sawada T; Kato Y; Kobayashi H; Hashimoto Y; Watanabe T; Sugiyama Y; Iwasaki S
Bioconjug Chem; 1993; 4(4):284-9. PubMed ID: 8218485
[TBL] [Abstract][Full Text] [Related]
27. Folate-maytansinoids: target-selective drugs of low molecular weight.
Ladino CA; Chari RV; Bourret LA; Kedersha NL; Goldmacher VS
Int J Cancer; 1997 Dec; 73(6):859-64. PubMed ID: 9399666
[TBL] [Abstract][Full Text] [Related]
28. Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.
White BH; Whalen K; Kriksciukaite K; Alargova R; Au Yeung T; Bazinet P; Brockman A; DuPont M; Oller H; Lemelin CA; Lim Soo P; Moreau B; Perino S; Quinn JM; Sharma G; Shinde R; Sweryda-Krawiec B; Wooster R; Bilodeau MT
J Med Chem; 2019 Mar; 62(5):2708-2719. PubMed ID: 30735385
[TBL] [Abstract][Full Text] [Related]
29. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG.
Shao S; Tsai MH; Lu J; Yu T; Jin J; Xiao D; Jiang H; Han M; Wang M; Wang J
Bioorg Med Chem Lett; 2018 May; 28(8):1363-1370. PubMed ID: 29559276
[TBL] [Abstract][Full Text] [Related]
30. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
31. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
Dillon RL; Chooniedass S; Premsukh A; Adams GP; Entwistle J; MacDonald GC; Cizeau J
J Immunother; 2016 Apr; 39(3):117-26. PubMed ID: 26938945
[TBL] [Abstract][Full Text] [Related]
33. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
34. Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
Chari RV; Martell BA; Gross JL; Cook SB; Shah SA; Blättler WA; McKenzie SJ; Goldmacher VS
Cancer Res; 1992 Jan; 52(1):127-31. PubMed ID: 1727373
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
Barginear MF; John V; Budman DR
Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
[TBL] [Abstract][Full Text] [Related]
36. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
Perrino E; Steiner M; Krall N; Bernardes GJ; Pretto F; Casi G; Neri D
Cancer Res; 2014 May; 74(9):2569-78. PubMed ID: 24520075
[TBL] [Abstract][Full Text] [Related]
37. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Menchon G; Prota AE; Lucena-Agell D; Bucher P; Jansen R; Irschik H; Müller R; Paterson I; Díaz JF; Altmann KH; Steinmetz MO
Nat Commun; 2018 May; 9(1):2106. PubMed ID: 29844393
[TBL] [Abstract][Full Text] [Related]
38. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; Rossi D; Stussi G; Zucca E; Stathis A; Sloss CM; Bertoni F
Haematologica; 2019 Aug; 104(8):1633-1639. PubMed ID: 30733273
[TBL] [Abstract][Full Text] [Related]
39. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Tassone P; Goldmacher VS; Neri P; Gozzini A; Shammas MA; Whiteman KR; Hylander-Gans LL; Carrasco DR; Hideshima T; Shringarpure R; Shi J; Allam CK; Wijdenes J; Venuta S; Munshi NC; Anderson KC
Blood; 2004 Dec; 104(12):3688-96. PubMed ID: 15292058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
